药明康德荣膺CDP气候变化和水安全“双A”评级 | Bilingual News

上海，2026年1月19日 – 药明康德今日宣布，公司在2025年全球环境信息研究中心（CDP）评估中，在气候变化和水安全两个议题上均入选“A级”榜单。“A级”是CDP在相关领域授予的最高等级，这一认可充分体现了药明康德在气候变化和水资源管理方面的突出表现和对可持续发展的坚定承诺。

CDP作为一家全球性非营利组织，运营着全球唯一的独立环境信息披露系统，协助企业、资本市场、城市等管理其环境影响。CDP的年度评估流程与国际主流环境框架和信息披露标准保持一致，被广泛视为评估企业环境管理水平的权威标准。在本次评估中，药明康德首次入选气候变化“A级”榜单，并连续第二年荣登水安全“A级”榜单。

“同时入选CDP气候变化和水安全‘A级’榜单，体现了药明康德始终致力于推动医药领域的可持续创新。”药明康德联席首席执行官兼可持续发展委员会主席杨青博士表示：“作为全球医药和生命科学领域值得信赖的合作伙伴，药明康德在助力客户加速新药和突破性疗法问世的同时，持续将环境责任融入公司运营，致力于构建更健康、更可持续的未来。”

气候变化和水资源管理策略是药明康德践行环境保护承诺的重要组成部分。公司积极识别和应对环境相关的风险与机遇，不断强化环境管理体系，并切实保护运营基地及其周边自然环境。同时，药明康德围绕多个关键环境管理事项设立了目标，并通过监测和评估，实现量化分析与定期精准复盘。

作为创新的赋能者、客户信赖的合作伙伴以及全球健康产业的贡献者，药明康德和大多数客户一样，积极践行对可持续发展的承诺。截至目前，公司连续五年获得MSCI ESG领导力评级，并在最新的评估中首次获得“AAA”最高评级；连续四年入选道琼斯可持续发展指数（DJSI）；连续三年入选富时罗素社会责任指数系列；连续两年获得EcoVadis企业社会责任评级“金牌”认证。

此外，为进一步深化可持续发展承诺，药明康德持续拓展全球责任实践。公司温室气体减排近期目标成功通过了SBTi审核认证。同时，公司已加入联合国全球契约组织（UNGC），承诺支持全球契约十项原则；并加入制药供应链倡议（PSCI），成为PSCI供应商合作伙伴。

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）是全球医药及生命科学行业值得信赖的合作伙伴和重要贡献者，致力于通过提供一体化、端到端的新药研发和生产服务，推动全球医药健康创新。公司在亚洲、欧洲、北美等地均设有运营基地，依托独特的“CRDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来突破性的治疗方案。目前，公司的赋能平台正承载着来自全球30多个国家的约6,000家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com

WuXi AppTec Receives Double “A” Rating from CDP for Climate Change and Water Security Leadership

SHANGHAI, January 18, 2026 - WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced that it has been recognized on the “A List” for leadership in corporate transparency and performance across both Climate Change and Water Security by CDP (Carbon Disclosure Project). This recognition, which represents CDP’s highest rating in each category, underscores WuXi AppTec’s achievements in climate change and water resource management and its ongoing commitment to sustainable development.

CDP is a global non-profit that runs the world’s only independent environmental disclosure system for companies, capital markets, cities, states and regions to manage their environmental impacts. Its annual assessment process, aligned with major environmental frameworks and disclosure standards, is renowned as a global benchmark for evaluating companies’ environment-related activities. In the latest assessment, WuXi AppTec was named to CDP’s “A List” for Climate Change for the first time and included on CDP’s “A List” for Water Security for the second consecutive year.

“Earning CDP’s ‘A’ rating for both Climate Change and Water Security reflects WuXi AppTec’s unwavering commitment to sustainable pharmaceutical innovation,” said Dr. Steve Yang, Co-CEO of WuXi AppTec and Chairman of WuXi AppTec’s Sustainability Committee. “As a trusted partner to the global pharmaceutical and life sciences industry, we are dedicated to advancing life-saving therapies while integrating environmental stewardship throughout our operations.”

Climate change and water resource management strategies are core components of WuXi AppTec’s commitment to environmental protection. The Company actively addresses environmental risks and opportunities, continuously strengthens its environmental management systems, and effectively safeguards its operational sites and the surrounding natural environment. WuXi AppTec has set targets across multiple key environmental management areas and monitors progress to enable quantitative analysis and regular, precise reviews.

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates sustainability throughout its operations in alignment with the values of its customers and partners. The Company’s leadership in sustainability has been recognized by several prestigious organizations, notably receiving the MSCI ESG Leadership Rating for five consecutive years and achieving its first AAA rating in the most recent assessment. It has also been included in the Dow Jones Sustainability Index (DJSI) for four consecutive years and the FTSE4Good Index Series for three consecutive years. Additionally, the Company has received a Gold Medal in sustainability from EcoVadis for the second consecutive year.

Furthering its sustainability commitments, WuXi AppTec has received validation from the Science Based Targets initiative (SBTi) for its near-term emissions reduction targets. The Company is also a participant in the United Nations Global Compact (UNGC), supporting its ten principles, and serves as a supplier partner to the Pharmaceutical Supply Chain Initiative (PSCI).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。